title: Effect of diquafosol three per cent ophthalmic solution on tear film and corneal aberrations after cataract surgery.
abstract: BACKGROUND
  The aim was to evaluate the effect of diquafosol on tear film parameters and corneal aberrations after cataract surgery.
  
  
  METHODS
  This retrospective, comparative, observational case series included patients who underwent cataract surgery with or without peri-operative use of diquafosol three per cent ophthalmic solution. Patients in group I (31 eyes) were treated with diquafosol three per cent ophthalmic solution six times a day from one week before surgery to three months after surgery. Patients in group II (33 eyes) underwent cataract surgery without being administered diquafosol. Tear film break-up time (BUT), the ocular surface disease index (OSDI), the Oxford Scheme score, Schirmer's test I and corneal aberrations were determined before and at one and three months post-surgery.
  
  
  RESULTS
  In group I, the BUT, OSDI and Oxford Scheme score showed significant improvement at one and three months post-surgery (p = 0.002 for BUT at one month and three months, p = 0.023 and p = 0.049 for OSDI at one month and three months and p = 0.001 and p = 0.026 for Oxford Scheme at one month and three months), compared to baseline. In group II, the BUT, OSDI and Oxford Scheme score did not show any significant improvement during the follow-up period. In both groups, Schirmer's test I significantly decreased at three months post-surgery (p = 0.011 for group I and p = 0.034 for group II), compared to baseline. There were significant differences in the BUT and OSDI between the groups at three months post-surgery (p = 0.037 for BUT and p = 0.011 for OSDI). Regarding the corneal aberration, there were no significant differences between the groups at three months post-surgery.
  
  
  CONCLUSIONS
  Peri-operative application of diquafosol three per cent ophthalmic solution may prevent dry eye-related ocular surface changes accompanied by improvement of ocular symptom. No definite changes in corneal aberrations were noted.
authors.affiliation: Department of Ophthalmology, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, South Korea.|The Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, South Korea.
authors.forename: Hun
authors.initials: H
authors.lastname: Lee
authors.affiliation: The Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, South Korea.
authors.forename: Sang Myung
authors.initials: SM
authors.lastname: Kim
authors.affiliation: The Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, South Korea.
authors.forename: Seonghee
authors.initials: S
authors.lastname: Choi
authors.affiliation: The Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, South Korea.
authors.forename: Kyoung Yul
authors.initials: KY
authors.lastname: Seo
authors.affiliation: The Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, South Korea.|Corneal Dystrophy Research Institute, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, South Korea.
authors.forename: Eung Kweon
authors.initials: EK
authors.lastname: Kim
authors.affiliation: The Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, South Korea.
authors.forename: Tae-Im
authors.initials: TI
authors.lastname: Kim
mesh_terms: D057128:Aberrometry; D060433:Administration, Ophthalmic; D000368:Aged; D057108:Corneal Wavefront Aberration / Q000503:physiopathology*; D015352:Dry Eye Syndromes / Q000503:physiopathology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D019654:Lens Implantation, Intraocular; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D019990:Perioperative Care; D018918:Phacoemulsification; D011122:Polyphosphates / Q000008:administration & dosage*; D058912:Purinergic P2Y Receptor Agonists / Q000008:administration & dosage*; D012189:Retrospective Studies; D013666:Tears / Q000502:physiology*; D014500:Uracil Nucleotides / Q000008:administration & dosage*
chemical_list: D009883:Ophthalmic Solutions; D011122:Polyphosphates; D058912:Purinergic P2Y Receptor Agonists; D014500:Uracil Nucleotides; C403315:diquafosol
keywords: 
  OSDI
  ; cataract surgery; corneal aberrations; diquafosol; tear film